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The objective of this study is to compare the targeting ability of activated carbon nano-
particles and nanoliposomes, which are used as carriers for delivering docetaxel (DTX) to
the metastatic lymph nodes. In this study, we first prepared the DTX-loaded activated
carbon nanoparticles (DTX-AC-NPs) by modifying the activated carbon with nitric acid
oxidation and absorbing DTX in the concentrated nitro-oxide nanocarbon. We then pre-
pared DTX-loaded nanoliposomes (DTX-LPs) by the proliposome method. The physi-
ochemical properties of DTX-AC-NPs and DTX-LPs were carefully evaluated in vitro. The
metastatic lymph node uptake and the injection site retention were investigated by
analyzing the DTX concentration in metastatic lymph nodes and injection sites. The result
showed that DTX-AC-NPs and DTX-LPs with suitable and stable physicochemical proper-
ties could be used for in vivo lymph node targeting studies. DTX-AC-NPs significantly
increased DTX-AUC(0e24) and prolonged DTX-retention in metastatic lymph nodes
compared to DTX-LPs and non-modified activate carbon in vivo. This study demonstrated
activated carbon nanoparticles may be potential intralymphatic drug delivery system to
preferentially target regional metastatic lymph nodes.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Lymph node metastasis plays an active role in cancer
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conventional systemic chemotherapy cannot be effectively
delivered to the lymphatic system without dose-limiting tox-
icities [1]. Moreover, clinical evidences have shown the mini-
mal benefits of chemotherapy to treat lymph node metastasis
compared to its risks. Therefore, it is necessary to investigate
novel strategies to deliver chemotherapeutic drugs specif-
ically to the regional metastatic lymph nodes. Colloidal par-
ticles, such as liposomes and activated carbon particles,
which are known to be highly taken up by the lymphatic, can
be used as potential carriers for lymphatic chemotherapeutic
drug delivery [2,3].
The utilities of liposomes [4,5] and activated carbon parti-
cles [6,7] as carriers in lymphatic delivery have been widely
investigated in the past decade. Because liposomes can be
selectively absorbed by the lymphatics after local adminis-
tration [8], researchers have taken advantage of this property
to deliver liposomal contrast agents [9] and chemotherapeutic
drugs [10] to tumor metastatic lymphatic. The activated car-
bon particles quickly gather in the lymph nodes and dye them
black after macrophage phagocytosis due to their high affinity
to the lymphatic system. In recent years, this unique selective
distribution has been studied in many applications, such as
sentinel lymph node staining, drug carriers and thermother-
apy [11e13]. CNSI® (Carbon nanoparticles suspension injec-
tion) is already commercialized as an activated carbon
lymphatic tracer to track lymph nodes in the region of gastric
carcinoma. However, the activated carbon has poor dispersion
stability. Certain suspending compounds can serve as stabi-
lizing agents to remain their stability. In particular, it has been
reported that the nitric acid oxidation of the activated carbon
is able to improve the stability of the activated carbon, and the
modified activated carbon shows a good lymphatic targeting
[14].
Docetaxel is an antineoplastic agent derived from the
taxane class. It is one of the most important chemothera-
peutic agents for a broad range of human cancermalignancies
[15e17]. Due to the directly binding to the tubulin, docetaxel
disrupts microtubule, and then leads to mitotic arrest and
eventually causes apoptosis [18]. In clinical practice, docetaxel
has been successfully used, mostly for the treatment of non-
small cell lung cancer, locally advanced and metastatic
breast cancer, head and neck cancer, prostate cancer among
others [19e21]. Commercial formulation of docetaxel (i.e.
Taxotere®) by intravenous injection (i.v.) is often associated
with acute hypersensitive reactions, owing to the impact of
the drug itself and the presence of polysorbate-80 and ethanol
in the formulation, thus hindering its wide medical utility for
intravenous applications [22e25].
As two most commonly intralymphatic-targeted nano-
carriers, there is no previous study focusing on a systematic
comparison of activated carbon particles and liposomes in
terms of targeting delivery ability of docetaxel to metastatic
lymph node. To fill this gap, we prepared docetaxel-loaded
activated carbon nanoparticles (DTX-AC-NPs) and docetaxel-
loaded nanoliposomes (DTX-LPs). The DTX-AC-NPs were
produced by the nitric acid oxidation method. And DTX-LPs
were prepared by the proliposome method previously re-
ported [24]. The physicochemical properties of DTX-AC-NPs
and DTX-LPs were evaluated in vitro. Most importantly, thelymph node targeting ability of DTX-AC-NPs and DTX-LPs
were compared with the aspects of metastatic lymph node
uptake and the injection site retention after subcutaneous
administration.2. Materials and methods
2.1. Materials and animals
Docetaxel, the purity of which was over 99%, was purchased
from Lianyungang Gabriel Biochemical Technology Co., Ltd.,
China. Taxotere® was supplied by Sanofi-Aventis Group,
France. LIPOID S100 soybean phospholipids (SPC) were pur-
chased from Germany Lipoid GmbH Co. Ltd., Germany.
Cholesterol was purchased from Tianjin Bodi Chemical
Holding Co., Ltd., China. Activated carbon was purchased
from Taiji Ring Nano-Products Co., Ltd., China. All other
chemicals were of reagent grade and obtained
commercially.
BalB/c nude mice with 26e28 g of weight and 6e8 weeks of
age were supplied by the Experimental Animal Center of
Shenyang Pharmaceutical University. All animal experiments
were carried out according to the guidelines listed in “Princi-
ples of' Laboratory Animal Care” (NIH publication #85-23,
revised in 1985) and approved by the Animal Ethics Commit-
tee of Shenyang Pharmaceutical University.
2.2. Nanoliposome preparation
DTX-loaded liposomes (DTX-LPs) were prepared by the
carrier-deposition method according to our previous study
[26]. Briefly, a mixture of SPC/cholesterol/DTX (35/26/4, by
mM) were dissolved in anhydrous ethanol, then the resultant
solution and 1.50 g of 100 mmdry dextrose powder weremixed
and dried to freely flow by a rotary evaporator (RE52CS,
Shanghai Yarong Bio-chem Instruments, China). The dry
powder of DTX-LPs obtainedwas sieved by a 150 mmsifter. The
dry powder of DTX-LPs was reconstituted to form the lipo-
somes solution by the following method: the dry powder of
DTX-LPs was placed into 10 ml pH7.4 PBS with magnetic
stirring at 50rpm. The reconstituted DTX-LPs solution was
sonicated (400 W, 5 min), followed by using an Avanti Mini
Extruder (Avanti Polar Lipids) to extrude through poly-
carbonate membranes with 0.08 mm pore sizes. A gel chro-
matography column (1.0 cm  10 cm) was filled with
SephadexG-50 (GE Healthcare, US) which was applied to
separate the carrier systems and free drug.
2.3. Preparation of DTX-AC-NPs
2.3.1. Preparation of nitro-oxide nanocarbon
To obtain nitro-modified nanocarbon, the nitric acid oxidation
methodwas utilized. Briefly, 4 g activated carbons were added
into 35 ml ethyl acetate, followed with heating reflux under
60 C for 2 h and drying for 24 h. The acquired activated car-
bonswere treatedwith 30ml 10% nitric acid (V/V) and 0.1mol/
l NaOH for 1 h respectively, and then washed with distilled
water and dried for 24 h under 60 C. The dry activated carbon
was added into 30% nitric acid (V/V) with constant stirring.
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carbons were obtained. Nitro-modified activated carbons
were centrifuged for 30 min at 8000 rpm. Black supernatant
was dried in a vacuum dryer, then resuspended with distilled
water, and finally dried to obtain the nitro-modified
nanocarbon.
2.3.2. Preparation of DTX-AC-NPs
The DTX-loaded activated carbon nanoparticles (DTX-AC-
NPs) were prepared as follows. The nitro-modified nano-
carbon was added into 1 mg/ml DTX solution by sonicating
and then stirring for 45 min under 37 C, with a weight ratio of
nanocarbon to DTX ranging from 1:1 to 10:1 (W/W). DTX-AC-
NPs were filtered through a 0.22 mm filter membrane. The
DTX concentration of the filtrate was determined by the HPLC
method and isothermal adsorption curves were plotted to
determine an optimal weight ratio of nanocarbon to DTX. The
DTX-loaded activated carbon (DTX-ACs) was prepared by the
above method which adsorbed DTX in the original activated
carbon.2.4. Characterization of nitro-oxide nanocarbon
The nitration nanocarbonwas confirmed by FT-IR. To perform
the FT-IR spectrum analysis, the nitro-oxide nanocarbon
which was pressed into a sheet was placed in the sample hole
and scanned. The surface morphology of the nitro-oxide
nanocarbon powder and the activated carbon powder was
examined by a scanning electron microscope (SEM) (F1I-F,
Philips, Dutch). The particle size and the particle distribution
of the nitration nanocarbon and the activated carbon were
determined by using a laser particle size analyzer (LS-230,
Beckman Coulter, USA).
Dispersion stability of the nitration nanocarbon was
determined in the sedimentation experiment. The nitro-oxide
nanocarbon and activated carbon were dispersed in distilled
water (1:100, W/V) by ultrasound for 30 min and then centri-
fuged (3500 r/min, 15 min). The transmittance of supernatant
was measured at a wavelength of 720 nm by UV spectropho-
tometer (UV-2000, Unico, China). The stability index (D %) was
calculated using the following equations to evaluate disper-
sion stability: D ¼ (T0T1)/T0  100%, in which T1 was the light
transmittance of the sample; T0 was the transmittance of the
dispersion medium.2.5. Characterization of DTX-AC-NPs and DTX-LPs
The morphology of DTX-AC-NPs and DTX-LPs was investi-
gated using transmission electron microscopy (TEM) (JEM-
1200EX, Japan). The particle size and zeta potential of DTX-
ACs, DTX-AC-NPs and DTX-LPs were measured by laser light
scattering using a Zetasizer (Nano-ZS90, Malvern, England) at
25 C.
The drug entrapment efficiency (EE), drug loading effi-
ciency (LE) and drug loading (LD) of DTX-ACs, DTX-AC-NPs
and DTX-LPs were analyzed by the mini-column centrifu-
gation method according to our previous study [27]. DTX
was determined by the HPLC method. Each measurement
was carried out in triplicate. The EE, LE and LD werecalculated by the following equations according to mass
balance:
EE% ¼WEnveloped

WTotal  100%
LE% ¼WTotal Wunloading

WTotal  100%
LD% ¼WEnveloped

WLipids=Carbons  100%
WTotal was the total weight of DTX added; WEnveloped
was the weight of the loaded DTX in nanoliposome system;
Wunloading was theweight of the unloaded DTX in nanoparticle
system; WLipids/Carbons was the total weight of carriers.2.6. In vivo evaluation
2.6.1. Chromatography
DTX concentrations of the in-vivo samples were analyzed by
the HPLC instrument (Shimadzu, Japan) which was composed
of a SPD-20A UV detector, a SIL-10AF auto-sampler, and a LC-
10AT quaternary pump. Chromatographic conditions were set
to: Century SIL C18-BDS column (200  4.6 mm, 5 mm) (Bis-
choff, Germany) was used at 25 C. The mobile phase con-
sisted of acetonitrile and water (55:45, V/V). The flow rate was
1.0 ml/min. The detection wavelength was 230 nm.
2.6.2. Nude mice bearing tumor metastatic lymph node model
BalB/c nudemice with 26e28 g of weight and 6e8 weeks of age
were used for in-vivo evaluation. Tumor metastatic lymph
node model was established according to previously reported
procedure [28]. The suspended Hela cells (2  106 cells in
0.2 ml of cell culture medium) were injected subcutaneously
via left hind foot pad in the BalB/c nude mice. The lymphatic
metastatic tumors were observed to form in the left (inocu-
lated side) popliteal and iliac metastatic lymph nodes after 8
weeks.
2.6.3. Animal experimental procedure
The lymphatic drainage and lymph node uptake ability of
DTX-ACs, DTX-AC-NPs and DTX-LPs were investigated in
nude mice bearing tumor lymph node metastasis. Using the
tumor metastatic lymph node model demonstrated in “Sec-
tion 2.6.2”, the nudemice bearingmetastatic lymphnodewere
randomly divided into 3 groups (DTX-ACs, DTX-AC-NPs and
DTX-LPs group, n¼ 6/group). DTX-ACs, DTX-AC-NPs andDTX-
LPs were subcutaneously (s.c.) injected via left foot pad with
the dose of 1 mg/kg DTX. At predetermined time post-
injection, the mice were sacrificed. The metastatic lymph
nodes (metastatic popliteal lymph nodes and metastatic iliac
lymph nodes) and foot (injection site) were immediately har-
vested. An aliquot (50 ul) of tissue homogenates was loaded
into an Eppendorf tube followed by the addition of 10 ul
paclitaxel solution (20 mg/ml) as the internal standard and
250 ml acetonitrile. The mixture was vortexed for 5 min and
centrifuged at 10,000 g for 10 min. Supernatants were ob-
tained through this procedure, and it was dried under a
stream of nitrogen and redissolved in 100 ul mobile phase,
vortexed for 3min, and centrifuged at 10,000g for 5min, and
then DTX concentration of the supernatant was analyzed
using HPLC as mentioned in “Section 2.6.1”.
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Statisticswere expressed asmean values± standard deviation
(SD). Non-compartmental Pharmacokinetic data analysis was
carried out by using DAS 2.0 software (Mathematical Phar-
macology Professional Committee of China, Shanghai, China).
Statistical analysis of this study was performed with ANOVA
using SPSS 11.5 software. Values of P < 0.05were considered to
be statistically significant.Fig. 1 e FT-IR spectra of original activated carbon and nitro-
oxide nanocarbon.3. Results and discussion
3.1. Preparation of DTX-AC-NPs and DTX-LPs
Proliposomes were defined as dry and free-flowing particles
that immediately form a liposomal dispersion on contact with
water [29,30]. Based on this concept, proliposomes were pre-
pared with a solution of drugs and lipids which were distrib-
uted into the micro-porous structure of carrier particles by
volatilizing the organic solvents. The DTX-LPs, prepared by
the proliposome method with dextrose powder as carriers,
had satisfactory physicochemical characteristics during
storage.
The DTX-AC-NPs were prepared by absorption method.
The result showed that when the ratio of nanocarbons to DTX
was more than 8:1, the DTX-adsorption was close to 99%,
which implied a nearly complete adsorption. According to the
adsorption equilibrium, Freundlich equation was fit and could
be expressed as follows: M¼69.880.1237 (r ¼ 0.9917).
3.2. Characterization of nitro-oxide nanocarbon
The FT-IR spectra for the original activated carbon and the
nitro-oxide nanocarbonwere shown in Fig. 1. The spectrum of
original activated carbon exhibited a broad, strong eOH
stretch band at 3413.3 cm1, which indicated that numerous
eOH groups were present in original active carbon. In the
spectrum of the nitro-oxide nanocarbon, the intensity of the
band at 3428.2 cm1 increased, which could be attributed to
the phenolic-OH groups generated after oxidation. Typical
features of nitro-oxide nanocarbon compared with the orig-
inal activated carbon showed four new peaks of the charac-
teristic peak position: a strongeNO2 symmetrical stretch band
at 1383.9 cm1, a strong eNO2 asymmetrical stretch band at
1591.5 cm1, a CeNO stretch band at 618.6 cm1 and a CeO
bend band at 1124.6 cm1, which demonstrated the successful
preparation of the nitro-oxide nanocarbon.
Fig. 2 illustrated that the surfacemorphology of the original
activated carbon and the nitro-oxide nanocarbon were
respectively detected by SEM at 100 and 1000 magnifica-
tions, respectively. There was a clear difference between
Fig. 2A (original activated carbon) and Fig. 2B (oxidized nano-
carbons). It showed that the particle diameter of the nitro-
oxide nanocarbon were significantly decreased and also
became more uniform than the original activated carbon.
The particle size distribution analysis of the original acti-
vated carbon and oxidized nanocarbons were shown in Fig. 3.
It revealed that the average particle size of original activated
carbon was 1.353 ± 0.643 mm and appeared double peaks
which implied uneven particle size in Fig. 3A. But the averageparticle size of oxidized nanocarbons was 80.5 ± 19 nm and
particle size was uniform in Fig. 3B.
Dispersion stability of the original and oxide activated
carbon was determined by the sedimentation experiment. In
conditions of un-centrifugation, stability factor of the original
activated carbon in aqueous systems was 95.4%. When orig-
inal activated carbonswere centrifuged for 30min, it had been
completely precipitated.While the stability factor of the nitro-
oxide nanocarbon was still 82.5% after 60 min centrifugation.
It implied that nitric acid oxidation greatly enhanced the
dispersion stability of the activated carbon in aqueous
systems.
3.3. Characterization of DTX-AC-NPs and DTX-LPs
The morphology of reconstituted DTX-LPs by TEMwas shown
in Fig. 4. It could be seen that the DTX-LPs after being recon-
stituted became the monolayer liposomes solution, and the
typical bilayer structure of liposome. DTX-AC-NPs were in
circular shape and well dispersed. The EE/LE, DL, particle size
and zeta potential of DTX-AC-NPs andDTX-LPswere shown in
the Table 1. The results showed that they both had a high EE/
LE and DL, which were suitable for loading DTX. Particle size
was the key factor for subcutaneous administrating for tar-
geting lymphatic system. The formation of too large particles
in the interstitial surroundings could impair lymphatic
drainage [31]. A similarity of particle sizes between DTX-AC-
NPs and DTX-LPs was shown in Table 1 which could mini-
mize the influence of the particle size on lymphatic targeting.
3.4. Method validation tests
Calibration curves for DTX in plasma, lymph nodes and foot
were obtained. Calibration equations, linear range and corre-
lation coefficients were presented in Table 2. The results
Fig. 2 e SEM photograph of original activated carbon (A) and nitro-oxide nanocarbon (B).
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quantification (LOQ) of plasma, lymph nodes, and foot were
10 ng/ml, 10 ng/mg, and 250 ng/mg respectively. The intra-day
and inter-day precisions of plasma, lymph nodes and foot of
high, medium, and low concentrations were within 15%,
which indicated that the method was reproducible. TheFig. 3 e The particle size and distribution of nitro-oxide
nanocarbon (A) and original activated carbon (B).extraction recoveries of DTX in plasma, lymph nodes, and foot
were 88.32%, 87.15% and 85.81%, respectively. Therefore, this
method for the analysis of biological samples exhibited a good
precision and a high recovery.
3.5. Uptake and pharmacokinetics in metastatic
popliteal lymph nodes
The DTX concentration in metastatic popliteal lymph nodes
and the non-compartmental pharmacokinetic parameters
were shown in Fig. 5B and Table 3. As shown in Fig. 5A, the
popliteal and iliac lymph nodes of nude mice bearing tumor
lymph nodemetastasis appeared lymphadenectasis. It proved
that the animal model was successfully established. The max
concentrations of three formulations were obtained at 30min.
When the time continued to increase, the DTX-loaded carriers
had transferred to the next lymph node via the lymphatic
circulation. Therefore, the concentration of DTX reduced.
Comparing with DTX-ACs group, the DTX concentration-time
curves of DTX-AC-NPs and DTX-LPs groups revealed a slow
downward trend. DTX concentrations of DTX-AC-NPs and
DTX-LPs groups at any time-point were clearly higher than
DTX-ACs group in metastatic lymph node. Before the 24 h
time-point, the drug retentions in DTX-AC-NPs and DTX-LPs
group were similar, but were unable to be detected in DTX-
ACs group after 12 h post-injection. After the 24 h time-
point, the drug retention of DTX-AC-NPs group appeared to
be more than that of DTX-LPs group.
The non-compartmental pharmacokinetic parameters
were shown in Table 3. The Cmax of three formulations could
be observed at 30 min (Tmax). AUC(0e48 h) values indicated a
higher amount of DTX in DTX-AC-NPs group disposed in
metastatic popliteal lymph nodes than DTX-ACs and DTX-LPs
(5.273-fold (P  0.05) and 1.341-fold increase). The results
showed that DTX-AC-NPs showed more metastatic lymph
node uptake compared with DTX-ACs and DTX-LPs. Mean
residence time (MRT) of DTX was significantly prolonged
(P 0.05) by loading in DTX-AC-NPs and DTX-LPs compared to
load in DTX-ACs. AndMRTwas further prolonged by DTX-AC-
NPs group. It showed that DTX in DTX-AC-NPs group resided
inmetastatic lymph nodes for a longer time than DTX-AC-NPs
and DTX-LPs groups. The clearance (CL) was significantly
decreased in DTX-AC-NPs compared with DTX-AC-NPs and
Fig. 4 e TEM photograph of DTX-LPs (A) and DTX-AC-NPs (B) £ 20 K magnification.
Table 1 e Physicochemical properties of DTX-ACs, DTX-LPs and DTX-AC-NPs (Mean ± SD, n ¼ 3).
Formula EE/LE (%) DL (%) Particle Size Zeta potential (mV)
DTX-ACs 87.26 ± 3.78 3.71 ± 0.42 1.353 ± 0.643 mm 0.46 ± 0.18
DTX-AC-NPs 94.33 ± 1.67 4.46 ± 0.56 80.27 ± 3.61 nm 9.34 ± 1.95
DTX-LPs 92.85 ± 2.58 4.25 ± 0.31 88.52 ± 2.19 nm 0.02 ± 0.03
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(P  0.01).3.6. Uptake and pharmacokinetics in metastatic iliac
lymph nodes
The DTX concentrations in metastatic iliac lymph nodes
were shown in the Fig. 5C and the non-compartmental
pharmacokinetic parameters were in the Table 2. The DTX
concentration curve of metastatic iliac lymph nodes was
similar to that of metastatic popliteal lymph nodes. The max
concentrations of three formulations were also obtained at
30 min. The AUC(0e48 h) values indicated a higher amount of
DTX in DTX-AC-NPs group disposed in iliac metastatic lymph
nodes than DTX-ACs and DTX-LPs (33.828-fold (P  0.01) and
1.530-fold increase). And DTX-ACs had the worst lymphatic
drainage ability compared with DTX-LPs and DTX-AC-NPs.
Comparing with metastatic popliteal lymph nodes, the
AUC(0e48 h) values of three formulations decreased in meta-
static iliac lymph nodes, by 9.257-fold decrease in DTX-ACsTable 2 e Calibration curves of DTX for plasma, lymph nodes a
Samples Calibration curves
Plasma Ai/As ¼ 0.30427C þ 0.0157
Lymph nodes Ai/As ¼ 0.369428C þ 0.004
Foot Ai/As ¼ 0.337091C þ 0.016group, 1.646-fold decrease in DTX-LPs group and 1.443-fold
decrease in DTX-AC-NPs group, respectively. It implied that
one portion of administration dose, which was not taken in
metastatic popliteal lymph nodes, was transferred to the iliac
lymph nodes and then taken in them. And another portion
was transferred by microcirculation and trans-cellular
pathway.3.7. Injection site retention
The DTX concentration of injection site was shown in Fig. 6.
From Fig. 6, we could see that drug retention in DTX-ACs
group was larger than that in DTX-LPs and DTX-AC-NPs
groups. 83.45 ± 8.71% and 87.14 ± 5.53% of DTX in DTX-LPs
and DTX-AC-NPs group was cleared from the injection site
at 30 min time-point, but which in DTX-ACs group was
95.39 ± 3.96%. DTX in three formulations at the injection site
gradually eliminated post-injection. DTX in DTX-LPs group
had the highest clearance compared with DTX-ACs and
DTX-AC-NPs groups. But the difference of clearance wasnd foot by HPLC method.
Calibration curves Correlation coefficients
0.01e12 mg mL1 0.9945
0.01e6 mg mL1 0.9992
0.25e25 mg mL1 0.9918
Fig. 5 e (A): metastatic popliteal lymph nodes (a), popliteal lymph nodes (b), metastatic iliac lymph nodes (c); DTX
concentrations in metastatic popliteal lymph nodes (B) and metastatic iliac lymph nodes (C) after subcutaneous
administration at the dose of 1 mg/g. The data were mean values ± SD.
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(P > 0.05). At 48 h after administration, DTX-ACs group still
had 85.41 ± 6.01% of the residues at the injection site,
however, 42.55 ± 1.96% and 48.45 ± 5.12% of the remaining
DTX in DTX-LPs and DTX-AC-NPs group at the injection site.
For the injection site, the clearance of three formulations
was in descending order of DTX-LPs, DTX-AC-NPs and DTX-
ACs.Table 3 e Pharmacokinetic parameters in metastatic popliteal a
at the dose of 1 mg/kg (Mean ± SD, n ¼ 6).
DTX-ACs
AUC(0e24 h) mg/g  h 2.379 ± 0.594
MRT(0e24 h) h 6.317 ± 0.341
V L/kg 4.764 ± 1.704
CL L/h/kg 0.436 ± 0.112
Tmax h 0.5
Cmax mg/g 0.981 ± 0.256
DTX-ACs
AUC(0e24 h) mg/g  h 0.257 ± 0.07
MRT(0e24 h) h 1.574 ± 0.05
V L/kg 6.276 ± 1.59
CL L/h/kg 4.072 ± 1.15
Tmax h 0.5
Cmax Mg/g 0.143 ± 0.03
The following parameters were included AUC, area under the plasmae
distribution volumes of the compartment, CL, clearance; Cmax, maximu
concentration.4. Conclusion
In this study, we prepared DTX-loaded nanoliposomes by the
proliposome method, and DTX-loaded activated carbon
nanoparticles bymodifying nanocarbon. The activated carbon
wasmodified by nitric acid oxidation, and then by centrifuged
to obtain modified nanocarbon. We found that the modifiednd iliac lymph nodes after subcutaneously administration
Metastatic popliteal lymph nodes
DTX-LPs DTX-AC-NPs
9.353 ± 3.850 12.545 ± 4.885
8.653 ± 2.824 13.830 ± 0.077
87.304 ± 43.113 3.194 ± 0.570
0.12 ± 0.057 0.062 ± 0.035
0.5 0.5
1.59 ± 0.450 1.48 ± 0.650
Metastasis iliac lymph nodes
DTX-LPs DTX-AC-NPs
1 5.682 ± 1.916 8.694 ± 3.258
5 7.635 ± 2.638 13.306 ± 0.283
7 1.576 ± 0.603 0.091 ± 0.049
7 0.008 ± 0.010 4.647 ± 0.752
0.5 0.5
7 0.925 ± 0.225 1.193 ± 0.433
time curve; MRT, the mean residence time; t1/2-the half-life; V, the
m plasma concentration; Tmax, time to reach the maximum plasma
Fig. 6 e DTX-retention % dose in the injection sites after
subcutaneous administration at the dose of 1 mg/g. The
data were mean values ± SD.
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capacity than the original activated carbon. Thus DTX-AC-NPs
exhibited properties of uniform particle sizes, high drug-
loading and adequate dispersion stability.
The substances injected interstitially must traverse the
interstitium, which was the first obstacle of the intra-
lymphatic drug delivery system administered interstitially.
Particle size was one of the most important factors to deter-
mine the extent of absorption from the injection site after s.c.
injection [32e34]. Large particles (roughly larger than 0.1 mm in
diameter) had more difficulties to pass through the complex
structures of the interstitium and tend to be trapped at the site
of injection. Thus, in this study, DTX-LPs and DTX-AC-NPs
with under 0.1 mm particle size had more lymphatic
drainage than DTX-ACs. The interstitial space consisted of the
mucopolysaccharideswith low isoelectric points resulting in a
negative charge within a physiological pH range and the
presence of narrow aqueous tissue channels [35] allowed the
passage of nanocarriers by diffusion [36]. The nitric acid
oxidation equipped DTX-AC-NPs with more negative charge
and stronger hydrophilicity, which were benefited for the
DTX-AC-NPs to diffuse through these tissue channels. But
DTX-AC-NPs remained more drugs at the injection site than
DTX-LPs. It might be due to the slow destabilization and
degradation over time of the liposomes remaining at the in-
jection site, while losing their drug content.
The lymph node uptake was the other obstacle. Macro-
phage phagocytosis and reticular cells filtration affected in
lymph node uptake. It was known that the nanocarriers were
transported by the lymphatic and then were blocked by
macrophages phagocytosis and filtration effect in lymph
nodes. The metastatic lymph node localization was also
dependent on liposome size. In this study, the DTX-AC-NPs
and DTX-LPs were supposed to have similar metastasis
lymph node uptake due to similar particle diameter. But
because of the functional sustained release of activated car-
bon nanoparticles, there was a dynamic equilibrium betweenthe chemotherapy drugs loaded in nanocarbons with the free
drug around nanocarbons. As the consequence of this phe-
nomenon, DTX-AC-NPs extended DTX residence time in the
lymph node and had a larger AUC(0e48 h) which thus exhibited
better metastatic lymph node uptake.
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